comparemela.com
Home
Live Updates
AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohns Disease to European Medicines Agency (EMA) : comparemela.com
AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA)
/PRNewswire/ -- AbbVie (NYSE:ABBV) today announced it has submitted an application to the European Medicines Agency (EMA) seeking approval for risankizumab...
Related Keywords
,
Gastroenterol Hepatol ,
Tom Hudson ,
Access Economics Pty ,
Instagram ,
Abbvie Ltd ,
Linkedin ,
Twitter ,
Boehringer Ingelheim ,
Exchange Commission ,
European Union ,
Value In Health ,
Allergan ,
European Medicines Agency ,
Facebook ,
Crohn Colitis Foundation Of America ,
World Congress ,
Safety Information ,
Allergan Aesthetics ,
Private Securities Litigation Reform Act ,
Quarterly Reports ,
Digestive Disease Week ,
Virtual Conference ,
European Gastroenterology Week Virtual ,
Risankizumab Versus Treatment Withdrawal ,
Year Double Blinded Results ,
Rev Gastroenterol ,
Inflammatory Bowel ,
Colitis Foundation ,
Global Diagnosed Prevalence ,
Economic Costs ,
Participants With Moderately ,
Severely Active Crohn ,
Disease Who Failed Prior Biologic ,
Participants With Crohn ,
Study Comparing Risankizumab ,
Inadequate Response ,
Biologic Therapy ,
Placebo Controlled Induction Study ,
Severely Active Ulcerative ,
Abbvie ,
comparemela.com © 2020. All Rights Reserved.